期刊
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
卷 69, 期 3, 页码 264-269出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0000000000000607
关键词
tenofovir; genital tract; HIV; protection; adherence
资金
- Centre for the AIDS Programme of Research in South Africa (CAPRISA)
- United States Agency for International Development (USAID)
- FHI [GPO-A-00-05-00022-00, 132119]
- TIA (Technology Innovation Agency), a biotechnology center of the South African Department of Science and Technology
- Fogarty International Center, National Institutes of Health [D43TW00231]
- UNC Center for AIDS Research, an NIH [P30 AI50410]
- Gilead Sciences Grant [CO-US-106-0104]
Objective:The CAPRISA 004 trial showed that coitally dosed tenofovir 1% gel reduced HIV acquisition by 39% overall and 54% when used consistently. The objective of this analysis was to ascertain its pharmacokinetic-pharmacodynamic relationship to protect against HIV acquisition.Design:Genital and systemic tenofovir concentrations in 34 women who acquired HIV (cases) were compared with 302 randomly selected women who remained HIV uninfected (controls) during the CAPRISA 004 trial. In total, 336 cervicovaginal fluid (CVF), 55 plasma, and 23 paired cervical and vaginal tissue samples were assayed by validated methods for tenofovir and tenofovir diphosphate (tenofovir-DP) detection.Results:Tenofovir was detected in the genital tract in 8 (23.5%) cases and 119 (39.4%) controls (P = 0.076). Among those with detectable genital tract tenofovir, the median CVF concentrations were 97% lower in cases compared with controls, 476 versus 13,821 ng/mL (P = 0.107). A total of 14.7% (5/34) of cases and 32.8% (99/302) of controls were found to have tenofovir CVF concentrations above 100 ng/mL [odds ratio (OR): 0.35, P = 0.037]. At a higher threshold, 8.8% (3/34) of cases and 26.2% (79/302) of controls were found to have tenofovir CVF concentrations above 1000 ng/mL (OR: 0.27, P = 0.036). Plasma tenofovir concentrations were <1 ng/mL in all women and were detected only in controls (16.7%) and not in cases (0%), (P = 0.031). Returned used tenofovir gel applicators and CVF concentrations were correlated (Spearman r = 0.22, P = 0.001).Conclusions:A tenofovir concentration of 100 ng/mL in CVF was associated with 65% (95% CI: 6% to 87%) protection against HIV, whereas a 1000 ng/mL concentration correlated with 76% (95% CI: 8% to 92%) protection against HIV infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据